Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?
| Autor: | Olivier Caliez, Daniel Pietrasz, Feryel Ksontini, Solène Doat, Jean-Marc Simon, Jean-Christophe Vaillant, Valerie Taly, Pierre Laurent-Puig, Jean-Baptiste Bachet |
|---|---|
| Přispěvatelé: | TALY, Valerie, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Paul Brousse, Institut Salah Azaiz [Tunis] (ISA) |
| Rok vydání: | 2022 |
| Předmět: |
Hepatology
Gastroenterology [SDV.CAN]Life Sciences [q-bio]/Cancer Adenocarcinoma Prognosis Circulating Tumor DNA Pancreatic Neoplasms Prognostic markers [SDV.CAN] Life Sciences [q-bio]/Cancer Borderline resectable and locally advanced pancreatic cancer Biomarkers Tumor Humans Neoplasm Recurrence Local Neutrophil-to-lymphocyte ratio Biomarkers |
| Zdroj: | Digestive and Liver Disease Digestive and Liver Disease, 2022, 54 (10), pp.1428-1436. ⟨10.1016/j.dld.2022.01.126⟩ |
| ISSN: | 1590-8658 |
| DOI: | 10.1016/j.dld.2022.01.126 |
| Popis: | International audience; Background: prognostic biomarkers could be useful to better select patients with borderline resectable (BR) or locally advanced (LA) pancreatic adenocarcinoma (PA) for chemoradiotherapy (CRT) and/or secondary resection.Aims: The main objective of this work was to study characteristics, received treatments and prognostic of patients with BR or LA PA according to their baseline circulating tumor DNA status and, for secondary objective, neutrophil-to-lymphocyte Ratio (NLR).Methods: ctDNA status at baseline was determined using Next Generation Sequencing in a consecutive monocentric cohort of patients with a BR or LA PA.Results: 69 patients were included, 31 with BR PA and 38 with LA PA. 14 (20.3%) patients had baseline positive ctDNA. Five (7.8%) patients had NLR> 5. Patients with positive ctDNA had 3.7 months shorter progression free survival (p = 0.006). Patients with positive ctDNA had earlier progression after the beginning of CRT (4.4 vs 7.1 months; p = 0.068) and shorter relapse free survival after secondary resection (9.2 vs 22.9 months; p = 0.016).Conclusions: positive ctDNA at baseline was associated with a worse prognosis in patients with BR or LA PA. These data are exploratory and must be confirmed in further prospective trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect